BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18059374)

  • 1. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.
    Karimi K; Boudreau JE; Fraser K; Liu H; Delanghe J; Gauldie J; Xing Z; Bramson JL; Wan Y
    Mol Ther; 2008 Feb; 16(2):411-8. PubMed ID: 18059374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNγ-producing NK Cells.
    Karimi K; Boudreau JE; Fraser K; Liu H; Delanghe J; Gauldie J; Xing Z; Bramson JL; Wan Y
    Mol Ther; 2008 Feb; 16(2):411-418. PubMed ID: 28178541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
    Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
    Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
    Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
    Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction.
    Adam C; King S; Allgeier T; Braumüller H; Lüking C; Mysliwietz J; Kriegeskorte A; Busch DH; Röcken M; Mocikat R
    Blood; 2005 Jul; 106(1):338-44. PubMed ID: 15769894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
    Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
    J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DC therapy induces long-term NK reactivity to tumors via host DC.
    Shimizu K; Fujii S
    Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV16 CTL epitope peptide-activated dendritic cell and natural killer co-culture for therapy of cervical cancer in an animal model.
    Hu YX; Li M; Jia XH; Du QX; Miao FT; Yao L; Shen JD
    Asian Pac J Cancer Prev; 2013; 14(12):7335-8. PubMed ID: 24460298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.
    Wong JL; Mailliard RB; Moschos SJ; Edington H; Lotze MT; Kirkwood JM; Kalinski P
    J Immunother; 2011 Apr; 34(3):270-8. PubMed ID: 21389871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients.
    Lapenta C; Donati S; Spadaro F; Castaldo P; Belardelli F; Cox MC; Santini SM
    J Immunol; 2016 Aug; 197(3):795-806. PubMed ID: 27357153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced therapeutic effects against murine colon carcinoma induced by a Colon 26/Ag85A-CD226 tumor cell vaccine.
    Li Y; Yang F; Sang L; Zhu J; Han X; Shan F; Li S; Zhai J; Wang D; Lu C; Sun X
    Oncol Rep; 2015 Oct; 34(4):1795-804. PubMed ID: 26238268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
    Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
    J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.